Aibing Xu
Nantong, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Text-guided few-shot liver and tumor segmentation.
Journal: Frontiers in digital health
Published: March 05, 2026
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
Journal: European journal of medical research
Published: May 06, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
Journal: Signal transduction and targeted therapy
Published: January 18, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 16, 2024
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 26, 2024
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Journal: Frontiers in immunology
Published: June 12, 2023
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.
Journal: Liver cancer
Published: March 08, 2023
Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
Journal: Clinical Medicine Insights. Oncology
Published: December 13, 2022
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 29, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Journal: The Lancet. Oncology
Published: February 02, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 28, 2021
Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis.
Journal: BioMed research international
Published: April 26, 2020
Last Updated: 09/26/2026